The data thus far suggest that piclidenoson and namodenoson could potentially be the first A3AR agonists to achieve FDA approval and provide clinicians with new oral and safe drugs in the arsenal for fighting psoriasis (piclidenoson), HCC and NASH (namodenoson). This evidence concerns the gene ADORA3 and metabolic dysfunction-associated steatohepatitis.